Atea Pharmaceuticals Borrows $65 Million As Further Loans Hinge On Hepatitis C Milestones
The financing carries a 9.35% minimum interest rate and pledges substantially all assets, including intellectual property.
Atea Pharmaceuticals, which develops oral antiviral drugs, borrowed $65 million Friday under an agreement with Hercules Capital and participating lenders offering up to $200 million, according to an SEC filing filed Monday. Atea expects the financing, alongside its current operating plan, to support planned operations into mid-2028 as it prepares for a potential U.S. launch of its hepatitis C treatment.
More Cash Depends On Drug Progress
Access to the remaining loans depends on clinical, financing and commercial milestones—or lender discretion. Atea can borrow up to $35 million more if its ongoing late-stage trial of bemnifosbuvir and ruzasvir succeeds before a specified deadline in the second half of 2027.
Other advances require a financing milestone and progress in developing and commercializing the combination. The amounts available under those portions of the agreement depend on borrowing under the other portion; a final allocation of up to $30 million rests entirely with the lenders.
Atea starts with a substantial cash base: it held $219.5 million in cash, cash equivalents and investments as of June 30, 2026.
The Cost Of Backing The Launch
The debt carries a 9.35% minimum annual interest rate. The floating rate equals prime plus 2.35% when that produces a higher rate, and interest is payable monthly. Atea pledged substantially all its assets, including intellectual property, as collateral.
Atea must pay a $650,000 upfront fee, plus a fee of 1% on subsequent advances. Prepayments can trigger fees, and an additional charge comes due when the loans are prepaid, mature or become immediately payable following a default.
For the initial 48 months, Atea pays interest without repaying principal. Meeting a specified commercial milestone can extend that arrangement through maturity on November 1, 2031.
Cash requirements begin on October 1, 2027, with an exemption when Atea meets a specified market-value threshold. A separate performance requirement begins six months after FDA approval of the combination: Atea must meet minimum drug-sales targets or alternative cash requirements. A default can allow lenders to demand immediate repayment.
Hepatitis C Drives The Funding Plan
Atea has no approved products for sale. Its hepatitis C program combines bemnifosbuvir and ruzasvir, while AT-587 targets chronic hepatitis E in immunocompromised patients and has not entered human trials.
The hepatitis C program includes late-stage studies in the U.S. and Canada and outside North America, comparing Atea’s regimen with sofosbuvir and velpatasvir. Atea has described results from its completed study as positive.
Founder and CEO Jean-Pierre Sommadossi linked the financing to Atea’s 2028 U.S. launch goal and its intended path to profitability.
Atea expects results from its second late-stage hepatitis C trial in early 2027 and plans to submit an FDA approval application in mid-2027.
Sources
- 8-K Filing — Atea Pharmaceuticals, Inc. (AVIR) — SEC EDGAR
- Atea Pharmaceuticals Secures Credit Facility for Up to $200 — globenewswire.com